Glufosfamide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Glufosfamide
DrugBank Accession Number
DB06177
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 383.16
Monoisotopic: 382.0463434
Chemical Formula
C10H21Cl2N2O7P
Synonyms
  • Glufosfamide
External IDs
  • D 19575
  • D-19575

Pharmacology

Indication

Investigated for use/treatment in pancreatic cancer, solid tumors, breast cancer, colorectal cancer, brain cancer, lung cancer, ovarian cancer, and sarcoma.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Hexoses
Alternative Parents
Phosphoric monoester diamides / Phosphate esters / Oxanes / Secondary alcohols / Polyols / Oxacyclic compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organochlorides
show 3 more
Substituents
Alcohol / Aliphatic heteromonocyclic compound / Alkyl chloride / Alkyl halide / Hexose monosaccharide / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic phosphoric acid amide / Organic phosphoric acid derivative
show 12 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
1W5N8SZD9A
CAS number
132682-98-5
InChI Key
PSVUJBVBCOISSP-SPFKKGSWSA-N
InChI
InChI=1S/C10H21Cl2N2O7P/c11-1-3-13-22(19,14-4-2-12)21-10-9(18)8(17)7(16)6(5-15)20-10/h6-10,15-18H,1-5H2,(H2,13,14,19)/t6-,7-,8+,9-,10+/m1/s1
IUPAC Name
(2S,3R,4S,5S,6R)-2-({bis[(2-chloroethyl)amino]phosphoryl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O

References

General References
  1. Veyhl M, Wagner K, Volk C, Gorboulev V, Baumgarten K, Weber WM, Schaper M, Bertram B, Wiessler M, Koepsell H: Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2914-9. [Article]
ChemSpider
110215
ChEMBL
CHEMBL2107143
ZINC
ZINC000003918137
Wikipedia
Glufosfamide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentPancreatic Cancer1
3RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentLung Cancer1
2CompletedTreatmentPancreatic Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.05 mg/mLALOGPS
logP-1.4ALOGPS
logP-2.4Chemaxon
logS-1.6ALOGPS
pKa (Strongest Acidic)12.17Chemaxon
pKa (Strongest Basic)-0.94Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count6Chemaxon
Polar Surface Area140.51 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity78.35 m3·mol-1Chemaxon
Polarizability34.33 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0600-9826000000-6012e94000dc59cfa740
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0119000000-06ed2df653a3780cb0a5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0009000000-a90dedb8b95fc654c4fc
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00yi-0922000000-69d7379d0c15114d2f73
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4l-2900000000-e0238a185140a16a2f8d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-08mi-6890000000-52ab8ccfb3f3407674dc
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000f-0910000000-9c9b1d431e39bfa58837
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-175.23528
predicted
DeepCCS 1.0 (2019)
[M+H]+177.59328
predicted
DeepCCS 1.0 (2019)
[M+Na]+185.44235
predicted
DeepCCS 1.0 (2019)

Drug created at March 19, 2008 16:15 / Updated at February 21, 2021 18:52